Company intelligence / Profile preview
Allorion Therapeutics
Natick, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Allorion Therapeutics is a clinical-stage biotech company developing next-generation precision medicines, primarily small molecule drugs targeting oncology and autoimmune diseases. Its lead program, ARTS‑021 (CDK2 inhibitor), is in Phase 1/2 clinical trials for advanced solid tumors. The company has also licensed out key assets to partners such as Avenzo Therapeutics and AstraZeneca. Preclinical data support the potential best-in-class status of its CDK2 inhibitor, with additional programs targeting TYK2 and EGFR mutations advancing through preclinical stages.[6][9]
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small molecules[3][5][10]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Avenzo Therapeutics — global license for AVZO‑021 (ARTS‑021) and an option on an additional preclinical program. Deal value potentially over $1 billion including milestones.[9]AstraZeneca — exclusive option/license agreement for novel preclinical-stage EGFR L858R allosteric inhibitor program.[6]
Beyond the preview
Go deeper on Allorion Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allorion Therapeutics.